Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease - Wikidata - awgldk - TriplyDB

Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease

Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease

http://www.wikidata.org/entity/Q34682391

about

Mouse models of Parkinson's disease associated with mitochondrial dysfunction Mitochondrial dysfunction and oxidative stress in Parkinson's disease Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's Disease Amantadine ameliorates dopamine-releasing deficits and behavioral deficits in rats after fluid percussion injury Parkinson's disease: animal models and dopaminergic cell vulnerability L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease Dopaminergic and glutamatergic microdomains in a subset of rodent mesoaccumbens axons.Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons.Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons.Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease Norepinephrine activates dopamine D4 receptors in the rat lateral habenula.Loss of feedback inhibition via D2 autoreceptors enhances acquisition of cocaine taking and reactivity to drug-paired cues.Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons.Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease Attenuated response to methamphetamine sensitization and deficits in motor learning and memory after selective deletion of β-catenin in dopamine neurons.PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry.Flavonoid regulation of HCN2 channels.Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons.Effects of Feeder Cells on Dopaminergic Differentiation of Human Embryonic Stem Cells.Parkinson's disease mouse models in translational research.Dysfunctional HCN ion channels in neurological diseases.Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.Ex Vivo Measurement of Electrically Evoked Dopamine Release in Zebrafish Whole Brain.HCN Channels Modulators: The Need for Selectivity.Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.Review: Central nervous system involvement in mitochondrial disease The Hyperpolarization-Activated Current Determines Synaptic Excitability, Calcium Activity and Specific Viability of Substantia Nigra Dopaminergic Neurons.Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study.Parkinson's disease: experimental models and reality.Dopamine Release Impairment in Striatum After Different Levels of Cerebral Cortical Fluid Percussion Injury.N-methyl N-nitrosourea induced functional and structural alterations in mice brain-role of curcumin.The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms.Dynamical Mechanism of Hyperpolarization-Activated Non-specific Cation Current Induced Resonance and Spike-Timing Precision in a Neuronal Model.GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice.

P2860

Q26829851-C5F8EFA6-641C-4CFC-BEAB-DF907B719C15 Q27014051-6B9963A1-14B4-4CF2-973E-A982C18CCBD7 Q27316725-CB570088-49FF-40C9-B821-529E99B82897 Q27331447-47B9654C-21E0-4F25-B64F-7FE7DE767BBA Q28080503-39437B72-716F-444F-ACC0-27C7024CEA0E Q28602694-FE2718A8-4994-409C-A596-2439B1439B3A Q30372768-B78A4CFF-8305-423C-B026-FA9298F1C0B2 Q30472044-4F20D111-23C8-4B4D-A4E5-3238CB432253 Q30621394-F180EDBF-93FC-4AE8-8326-DE12BEAA174E Q33361464-69056D2B-0012-444C-8A17-BDEF382F15D8 Q34383447-1FBE6308-0771-4F0C-8167-2C33BAA55AA6 Q34970932-8468906B-60A2-4997-BBC7-A34FAA9DA9AC Q35117597-F696327C-C14A-4FE0-B9EA-C9C955C00C23 Q35421216-C898C561-B4ED-45BF-BC63-E37D46E4C35A Q35750220-86C1BA56-AD84-4F72-8DF7-4B7169AB355A Q35990732-8AA3C3FB-DE86-4F8C-B1F7-4AB8CB1DEC50 Q36126234-79F058CF-1F03-4CF2-B05F-483DDF3CECEA Q36218704-0E351865-020A-471A-8DB7-A415EBC67379 Q36610017-BDF162D3-413F-40DF-AB66-25AC83DB4A25 Q37008883-2A6A9D81-F937-469B-AAE4-A295A3B2B594 Q37317597-10B9C20B-BF95-4885-A3C4-E1910F648959 Q37466357-F379F70A-1AE6-4492-915B-A60044B8AC06 Q37516524-E3197F91-A242-4C58-9224-7E4DFF31CF42 Q37874160-1002D5E4-3F23-4A2E-AD25-74CDC259340B Q38389906-B6C6440D-8D54-454A-893C-1BBC53A6F300 Q38605280-62B5DFB6-FEA7-4E27-9B3D-89310FA4267B Q38708951-82621EB2-95AF-4D0A-9892-1A576E3E6F79 Q38724516-4F3B84C9-DD52-4D92-9572-B65E0CF2A761 Q38774251-A7325C51-1C5F-4185-B0D8-A19F6D8D5E14 Q38855994-A0B9DBE4-75FC-4B9B-A188-94336020F3D7 Q38861730-0999D811-8BC8-411E-9723-2E85C1F76DE3 Q41025017-90D56252-D6B1-4F8D-801C-96C7FDA26642 Q42499434-4D28DDEF-486A-44F5-9A6F-B75FF29D78A3 Q44650375-048BC76E-742E-4E5B-9012-48277B7397FF Q47389506-A25F7E02-DEDA-43D2-862D-B6AEF344EAE6 Q48558303-7B1B397E-E332-4C57-BE06-870FC4C58B3B Q48712152-39A6CE1C-8158-442E-BBFA-67D8F1463DE2 Q49823902-922C09E2-A803-4DEE-9691-BAB2B451C1FB Q52345461-E597BD34-6BF7-43D7-89DA-209F14FE9954 Q52721898-DB3E139D-95CB-4000-B28B-708FCB9EF300

P2860

Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease

http://www.wikidata.org/entity/Q34682391

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@ast

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@en

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@nl

type

label

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@ast

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@en

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@nl

prefLabel

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@ast

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@en

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@nl

P1433

Q34682391-FE497AB8-382A-45BB-A43C-0B639CFB14CB

P1476

Q34682391-F1C5E2B7-7607-4A29-96F3-3AC0D7FDF4E9

P2093

Q34682391-0382FEDA-BB98-41E1-9008-1A2E9527A88F

Q34682391-08D313C1-0400-4057-B66D-A3B6137D4E2D

Q34682391-28B5CB98-D1EA-4520-8141-75FE76ABFDE2

Q34682391-324B121E-D4BF-47C0-9D2C-D7518FF7A1AE

Q34682391-650DA4CB-0C5E-4ADD-A33F-F5470A86B91F

Q34682391-682BEDEC-139D-4CCE-A0DD-B9DC3F65DFBB

Q34682391-866EA830-8AB3-49A4-85DC-B02BA174E963

Q34682391-8784166F-B778-43EC-84B8-37D8C5C8BC2D

Q34682391-B6B645E1-3452-4E26-8FF5-637FD9894750

P2860

Q34682391-01110614-EDCF-4926-B920-E99B77B61F5D

Q34682391-01D987BA-9140-457E-8EC6-85F2F74CC402

Q34682391-03E3678C-434F-4F54-AC92-1E7B58413C08

Q34682391-07B49AB6-DE23-4F35-91F3-EC26A6D02551

Q34682391-08FE6A10-A1CE-4037-B03A-1F386340EA10

Q34682391-138239F5-9C8C-4B2D-B36D-607F415E65A1

Q34682391-281E214E-CCB4-4F04-81A3-89FF6062ACB2

Q34682391-2939E95E-D440-4985-987A-04EC794B7661

Q34682391-29CD1CC9-9CF5-4D38-8B07-CC327D457F57

Q34682391-2AD0585C-5BEC-456B-9A0E-FC2D8769D3BF

P304

Q34682391-38667D26-181C-4A10-A175-8ED6A9A2404C

P31

Q34682391-A5CD21EE-BFEC-4F32-AC2C-4D993BF88E6E

P356

Q34682391-6E7E9D0B-0C0C-41B4-B1DB-37D5FBABDBBB

P407

Q34682391-992D005C-8ACC-4049-8E87-A6BEB511F5DC

P433

Q34682391-F649CA81-E442-4390-BF79-950A9B1A5F69

P478

Q34682391-2D7CAF4A-CA04-4A05-9CF4-2F00E59FAEA2

P50

Q34682391-58C491AD-F502-4003-B2E0-6A81724AFDF2

Q34682391-C2D7A97B-F191-44EF-91B4-76C3B6AFD979

P577

Q34682391-7935AECF-A584-41D9-A388-BECD7BBF3B36

P5875

Q34682391-EFA459AD-5C53-4A2F-B289-FF353977DF47

P698

Q34682391-7470402C-6F82-487E-ACC3-F81F69CC135B

P921

Q34682391-47D4AEA4-9CFC-4EE6-A306-ED09834A7BE8

P932

Q34682391-90A6046E-F45A-4721-9542-315BFC3E5A39

P356

P1433

P1476

Impaired nigrostriatal functio ...... l model of Parkinson's disease

@en

P2093

Alexander F Hoffman

http://www.w3.org/2001/XMLSchema#string

Barry J Hoffer

http://www.w3.org/2001/XMLSchema#string

Cameron H Good

http://www.w3.org/2001/XMLSchema#string

Carl R Lupica

http://www.w3.org/2001/XMLSchema#string

Cristina M Bäckman

http://www.w3.org/2001/XMLSchema#string

Lars Olson

http://www.w3.org/2001/XMLSchema#string

Sandra Gellhaar

http://www.w3.org/2001/XMLSchema#string

Toni S Shippenberg

http://www.w3.org/2001/XMLSchema#string

Vladimir I Chefer

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple Dopamine Functions at Different Time Courses

Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells

Profound neuronal plasticity in response to inactivation of the dopamine transporter

Parkinson's disease: mechanisms and models

High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice

Real-time measurement of dopamine fluctuations after cocaine in the brain of behaving rats.

Mechanism of toxicity in rotenone models of Parkinson's disease.

MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease

Parkinson's disease: Exit toxins, enter genetics

P304

1333-1344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.10-173625

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Nils-Göran Larsson

P577

2011-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49754009

http://www.w3.org/2001/XMLSchema#string

P698

21233488

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3058704

http://www.w3.org/2001/XMLSchema#string